Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA. Lynch TJ, et al. Among authors: okimoto ra. N Engl J Med. 2004 May 20;350(21):2129-39. doi: 10.1056/NEJMoa040938. Epub 2004 Apr 29. N Engl J Med. 2004. PMID: 15118073 Free article.
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib.
Kwak EL, Sordella R, Bell DW, Godin-Heymann N, Okimoto RA, Brannigan BW, Harris PL, Driscoll DR, Fidias P, Lynch TJ, Rabindran SK, McGinnis JP, Wissner A, Sharma SV, Isselbacher KJ, Settleman J, Haber DA. Kwak EL, et al. Among authors: okimoto ra. Proc Natl Acad Sci U S A. 2005 May 24;102(21):7665-70. doi: 10.1073/pnas.0502860102. Epub 2005 May 16. Proc Natl Acad Sci U S A. 2005. PMID: 15897464 Free PMC article.
Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials.
Bell DW, Lynch TJ, Haserlat SM, Harris PL, Okimoto RA, Brannigan BW, Sgroi DC, Muir B, Riemenschneider MJ, Iacona RB, Krebs AD, Johnson DH, Giaccone G, Herbst RS, Manegold C, Fukuoka M, Kris MG, Baselga J, Ochs JS, Haber DA. Bell DW, et al. Among authors: okimoto ra. J Clin Oncol. 2005 Nov 1;23(31):8081-92. doi: 10.1200/JCO.2005.02.7078. Epub 2005 Oct 3. J Clin Oncol. 2005. PMID: 16204011 Clinical Trial.
Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR.
Cohen EE, Lingen MW, Martin LE, Harris PL, Brannigan BW, Haserlat SM, Okimoto RA, Sgroi DC, Dahiya S, Muir B, Clark JR, Rocco JW, Vokes EE, Haber DA, Bell DW. Cohen EE, et al. Among authors: okimoto ra. Clin Cancer Res. 2005 Nov 15;11(22):8105-8. doi: 10.1158/1078-0432.CCR-05-0926. Clin Cancer Res. 2005. PMID: 16299242
Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752.
Smolen GA, Sordella R, Muir B, Mohapatra G, Barmettler A, Archibald H, Kim WJ, Okimoto RA, Bell DW, Sgroi DC, Christensen JG, Settleman J, Haber DA. Smolen GA, et al. Among authors: okimoto ra. Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2316-21. doi: 10.1073/pnas.0508776103. Epub 2006 Feb 6. Proc Natl Acad Sci U S A. 2006. PMID: 16461907 Free PMC article.
Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas.
Kwak EL, Jankowski J, Thayer SP, Lauwers GY, Brannigan BW, Harris PL, Okimoto RA, Haserlat SM, Driscoll DR, Ferry D, Muir B, Settleman J, Fuchs CS, Kulke MH, Ryan DP, Clark JW, Sgroi DC, Haber DA, Bell DW. Kwak EL, et al. Among authors: okimoto ra. Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4283-7. doi: 10.1158/1078-0432.CCR-06-0189. Clin Cancer Res. 2006. PMID: 16857803 Free PMC article.
42 results